Oncology funding

PhD normally within four years, or the specified medical qualification/clinical pathway; at least 12 months of postdoctoral or post-medical research. Applicants must have Swiss nationality, a qualifying Swiss degree, or at least 12 months of qualifying post-degree research/clinical work in Switzerland. Full regulations and extension rules apply.

Doctoral students or researchers awarded a doctorate in 2022 or later, employed or enrolled at a current SASUF+ partner university throughout the placement. The host must be a current partner university in the other country, with an invitation and home-supervisor or manager approval. Former partner institutions are not automatically eligible.

Mid-career researchers apply through an eligible Australian administering organisation. The PhD award date must fall between 1 March 2012 and 1 March 2022, or be equivalent after allowable career interruptions. A maximum of three applications is permitted. ARC medical-research exclusions apply.

Related doctorate and mentored fellowship by 1 July 2027; degree/residency completed on or after 1 July 2022, with leave exceptions. At least 50% research effort; academic, medical or research mentor worldwide; sufficient work status. Active AACR membership required. Further doctoral candidature, federal/for-profit employment, overlapping AACR grants, and current or previous instructor/assistant-professor-or-higher rank excluded; clinician MD instructor exception requires AACR eligibility review.

PhD completed no more than three years, or equivalent full-time years, before the deadline. Research must have been mainly undertaken in Tasmania or under a Tasmanian organisation. Anyone may nominate another person; self-nominations are excluded.

A relevant doctorate is required by the scholarship decision. Priority is given to applicants within three years of the doctorate; stated special circumstances can permit an earlier degree. A doctorate in molecular biology, genetics, biochemistry or a related field, molecular cloning and mammalian cell-culture experience, and strong English communication are required.

Applicants should have or expect a first or high upper-second-class degree, or overseas equivalent, with appropriate biochemistry and cell-biology knowledge. Home-rate fees are funded. Overseas applicants must qualify for Home fees or secure separate scholarship funding for the fee difference; self-funding that difference is not permitted.

Applicants to the TTP-T and TTP-P tracks must follow the current NSF 25-540 organizational and submission requirements.

An Austrian research institution applies for a researcher whose ERC Starting Grant 2026 proposal with that institution received an A rating but was not funded for budgetary reasons. Permanent professors or equivalent leaders, accepted permanent-professorship appointees, and former FWF START, ASTRA or ERC Starting Grant recipients are ineligible. ASTRA application rules also apply.

At least three independent entities in three different EU Member States or Horizon Europe associated countries, including at least one EU Member State. Austria is eligible. This call is for organisations, not individual students. Doctoral recruits must meet the programme’s degree and mobility rules.

Swedish citizens or permanent residents who received a doctorate within the past six years, or doctoral students expecting the degree within two years, may apply through this route. A host researcher at an eligible Japanese university or research institution is required. All academic fields are eligible.

Postdoctoral applicants normally within four years of the doctorate; experienced researchers within twelve years, with an independent publication record and a leadership role. German host agreement, facilities confirmation and assessment required. Prior Humboldt sponsorship excludes this route. Apply under the joint CAPES-Humboldt procedure.

The coordinator must hold a PhD and work at an Austrian member institution. Include at least one Austrian and one African member, all with 2026 fees paid. Participants must be PhD students or graduates. One proposal per coordinator; institutional endorsements and own funding are required.

Related doctoral degree and independent, non-mentored research position by 1 April 2027. Academic, medical or research host worldwide; work status must cover the term. Active AACR membership required by submission. No further doctoral candidature, U.S. federal or for-profit employment, or overlapping AACR grant.

Women founders or co-founders apply as individuals. Both residence and company establishment must be in an EU member state or Horizon Europe associated country. The company must have been incorporated before 1 January 2025. Only one prize category may be entered.

Canadian citizens, permanent residents or Protected Persons; eligible research graduate programme at an allocated Canadian institution. Normally 0–12 months of study by December 31; specific transition rules apply. First-class grades normally required, with institutional discretion. Prior agency master’s awards and specified Indigenous master’s awards exclude eligibility; only one CRTAS application per academic year.

University partnerships require eligible Canadian academics, non-academic partners and qualifying NSERC partnership-grant support in natural sciences or engineering. College partnerships require an eligible Canadian college, non-academic partners and implementation of results from a previous College and Community Innovation grant; broader research disciplines qualify. Self-nominations are excluded. A college research grants officer cannot nominate; previous Herzberg laureates are ineligible.

International students commencing or enrolled in a higher degree by research may apply. New applicants must submit a complete admission application and a separate scholarship application by the deadline; enrolled applicants submit the scholarship form.

Researchers of any nationality with 5–15 years since their certified successful PhD defence, subject to the 2027 call reference date and permitted extensions. A committed host in an eligible EU Member State or associated country must support an independent research team.

Approved MRFF Eligible Organisations only; projects must address one of the four streams and satisfy the Clinical Trials Activity 2026 guidelines.